Patients who undergo autologous stem cell transplantation (ASCT) for lymphoma have a significant risk of therapy-related acute myeloid leukemia and myelodysplasia (t-AML/MDS). Compared to that seen in other indications such as breast cancer, multiple myeloma or germ cell tumors, there is a substantially increased risk for t-AML/MDS following ASCT for lymphoma. This risk has largely been attributed to the extent of pre-transplant chemotherapy and radiation therapy. In many of the larger series to date, it has not been possible to directly implicate autologous transplantation itself as a risk factor for t-AML/MDS. Although pre-transplant therapy is certainly an important factor in the development of t-AML/MDS, specific components of the autologous transplantation procedure itself may also contribute to the risk of t-AML/MDS. Specifically, priming chemotherapy, total body irradiation, and the extensive cellular proliferation which occurs during engraftment may all play a role in the development of t-AML/MDS. Furthermore, there is an increasing body of evidence that certain inherited polymorphisms in genes governing drug metabolism, DNA repair and leukemogenesis may influence susceptibility to t-AML/MDS. In this paper, we review the evidence implicating the above risk factors for t-AML/MDS, present a potential mechanism for t-AML/ MDS and propose interventions to reduce the rate of t-AML/MDS in lymphoma patients.
Introduction
High-dose therapy with autologous stem cell transplantation (ASCT) can result in long-term disease-free and overall survival in patients with relapsed Hodgkin's and non-Hodgkin's lymphoma (NHL). As a result, in 2003, over 4000 autotransplants were performed for lymphoma in North America alone. With longer follow-up, it has become increasingly apparent that lymphoma patients have a significant risk of therapy-related leukemia and myelodysplasia (t-AML/MDS) following ASCT. The prognosis of therapy-related acute myeloid leukemia and myelodysplasia is extremely poor, with a median survival of 6-12 months. 28, 29 This is particularly unfortunate, since t-AML/MDS is by its nature an iatrogenic disease, and many affected patients are actually cured of their original malignancy. Clarification of the mechanisms underlying t-AML/MDS, and identification of possible interventions to reduce its incidence, would therefore have great potential to improve the care of patients with lymphoma.
Although an increased risk of t-AML/MDS after ASCT for lymphoma has been appreciated for over 10 years, whether ASCT directly increases the risk of t-AML/MDS has remained an unsettled question. Furthermore, the mechanism(s) responsible for t-AML/MDS following ASCT remain poorly understood. Factors such as age, extent of prior therapy and exposure to certain agents before ASCT (such as alkylating agents and total body irradiation (TBI)) are clearly important risk factors for t-AML/MDS in lymphoma patients. In addition, stresses imposed on hematopoietic stem cells (HSCs) during priming chemotherapy and engraftment are also likely to play a role in development of t-AML/MDS. Lastly, there is an emerging body of literature suggesting that inherited polymorphisms in genes governing drug metabolism, DNA repair and leukemogenesis may determine the risk of t-AML/MDS.
In this paper, we review the clinical features of t-AML/ MDS, as well as the literature showing that ASCT is indeed associated with a high rate of t-AML/MDS in lymphoma patients. We then discuss the evidence for and against ASCT directly contributing to the development of t-AML/ MDS, and briefly summarize the current state of knowledge of pharmacogenetic risk factors for t-AML/MDS. Lastly, we propose a possible mechanism for, and strategies that may decrease, the development of t-AML/MDS after ASCT for lymphoma.
Clinical features of t-AML/MDS
t-AML/MDS are serious complications that can occur following either conventional or high-dose chemotherapy. Between 5 and 20% of new AML cases worldwide are considered therapy related. 29, 30 The incidence of t-AML/ MDS in the US is rising, possibly owing to the aging of the population, longer survival after chemotherapy and/or more extensive use of chemotherapy drugs. Two classes of chemotherapy drugs are associated with t-AML. The topoisomerase II inhibitors are associated with t-AML with a short latency period (2-3 years) and frequent rearrangements involving the MLL gene at 11q23. 31 Alkylating agents are associated with t-AML of longer latency (5-8 years), frequently preceded by an MDS phase, and often associated with high-risk karyotypes such as abnormalities of chromosomes 5 and/or 7.
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Treatment-related MDS shows a higher risk of transformation into AML than de novo MDS, as well as more rapid progression to AML (approximately 6 months). The prognosis is generally poor with median survival of less than 1 year. Cytogenetic abnormalities involving chromosomes 5 or 7 are associated with a poor response to treatment; however, those without such abnormalities, or with balanced abnormalities, may be somewhat more responsive to antileukemic therapy. 29 
Therapy for t-AML/MDS
The dismal prognosis and poor response to treatment of t-AML/MDS were demonstrated in the large German Hodgkin's Lymphoma Study Group (GHSG) study, in which an overall survival of only 8% was seen at 2 years, regardless of whether patients received no therapy, conventional chemotherapy or myeloablative allogeneic transplantation. 33 Others have also reported very discouraging results with myeloablative allogeneic transplanation for t-AML/MDS. In a large series of t-AML/MDS patients who underwent myeloablative allogeneic transplantation (n ¼ 111) at the University of Washington, a 5-year diseasefree survival ranging from 8% (with TBI-based conditioning) to 30% (with targeted busulfan and cyclophosphamide conditioning) was observed. Treatment-related mortality (TRM) was high, ranging from 42 to 58%. 34 A French series reported a 28% event-free survival in 70 t-AML/ MDS patients who underwent myeloablative allogeneic transplantation. Again, a high TRM of 49% was seen. 35 Because of the high TRM, it is possible that improved results will be achieved with reduced-intensity or nonmyeloablative allogeneic transplantation approaches for t-AML/MDS. On the other hand, such approaches may result in higher relapse rates due to the decreased intensity of the conditioning regimens. Hopefully, these questions will be answered in the near future by ongoing research.
Incidence of t-AML/MDS after conventional therapy
Several large registry studies have shown that, in lymphoma patients who have been treated with conventional chemotherapy and chemoradiotherapy, t-AML/MDS occurs at a significant rate. Although lymphoma treatment protocols have evolved over time, general themes have emerged from such studies.
In Hodgkin's lymphoma (HL) patients, an increased risk of t-AML/MDS has been associated with chemotherapy regimens containing chlorambucil, mechlorethamine, lomustine, and teniposide-cyclophosphamide combinations. The number of cycles of chemotherapy, age greater than 35, and treatment before 1984 have also been identified as important risk factors for the development of t-AML/MDS in HL patients. Overall, a cumulative risk ranging from 0.8 to 13% has been seen after conventional therapy, with follow-up ranging from 6-20 years. 32, 33, [36] [37] [38] [39] [40] [41] [42] [43] [44] Interestingly, the GHSG found a fairly low incidence of t-AML/MDS (1% at nearly 5 years), likely reflecting a shift away from regimens containing mechlorethimine. 33 In NHL, associations have been identified between secondary AML and conventional doses of chemotherapeutic agents, either alone or in combination with total nodal/body irradiation. In general, a two-to eightfold increased risk of AML has been seen in patients who have been treated for NHL, compared with controls from the general population. As in HL, alkylating agents such as prednimustine, mechlorethamine, procarbazine and chlorambucil are associated with higher risks of t-AML/ MDS. [45] [46] [47] There are conflicting data regarding whether regimens with relatively low cumulative doses of cyclophosphamide (such as CHOP) increase the risk of t-AML/ MDS. 45, 47 Incidence of t-AML/MDS after ASCT Estimates of the incidence of t-AML/MDS range between 1 and 14% at 3-15 years, in patients who have undergone ASCT for lymphoma (see Table 1 ). The incidence of t-AML/MDS has varied widely with a large range of follow-up. Despite differences in how these incidences were calculated (actuarial versus cumulative incidences), a risk of up to 10% for t-AML/MDS in patients who underwent ASCT for NHL was found when all studies through 1999 were considered together in a recent meta-analysis. 48 An increased risk of t-AML/MDS has also been seen in patients following ASCT performed for other indications such as breast cancer, 49, 50 multiple myeloma 51 and germ cell tumors. 52 In general, the rate of t-AML/MDS seen after ASCT for these disorders is substantially lower than that observed in lymphoma patients who have undergone ASCT. An explanation underlying this observation is lacking, but possible explanations include (1) differences in the pre-transplant chemotherapy regimens given for these disorders, (2) enhanced survival after ASCT for lymphoma patients as compared with myeloma patients, resulting in more lymphoma patients at risk for t-AML/ MDS, (3) unique biological features of lymphoma that lead to enhanced susceptibility to t-AML/MDS following ASCT or (4) shared genetic factors that influence risk of both lymphoma and t-AML/MDS.
Clinical risk factors for t-AML/MDS in lymphoma patients
In several studies, attempts have been made to identify specific risk factors associated with higher rates of t-AML/ MDS after ASCT for lymphoma. As seen in Table 2 , a number of risk factors have been repeatedly identified, with increased age, TBI conditioning, and quantity of pretransplant therapy each reported in at least six studies. The strength of the association of each of these individual factors has varied among studies, making it unclear which factors are most critical in determining the risk of t-AML/ MDS. In a careful review, Armitage et al. 48 concluded that, unlike subtotal nodal irradiation or TBI, involved-field radiotherapy is unlikely to be associated with a significant risk of t-AML/MDS. However, the issue of whether the ASCT procedure itself contributes to an increased risk of t-AML/MDS has remained an unsettled question. The Table 1 Results from series evaluating risk of t-AML/MDS after ASCT for lymphoma (X5 year follow-up) Abbreviations: ASCT ¼ autologous stem cell transplantation; HL ¼ Hodgkin's lymphoma; NHL ¼ non-Hodgkin's lymphoma; t-AML/MDS ¼ therapyrelated acute myeloid leukemia and myelodysplasia; TBI ¼ total body irradiation. a Cumulative or actuarial incidences. b 'TBI' indicates that all patients in the study received TBI as part of conditioning regimen. c 'Non-TBI' indicates that 2% or fewer patients in the study received TBI. d Number of patients randomized to ASCT. evidence both against and for an increased risk of t-AML/ MDS owing to the ASCT procedure itself is presented separately below.
Evidence that pre-transplant therapy determines risk of t-AML/MDS
One hypothesis to account for the increased risk of t-AML/ MDS after ASCT for lymphoma states that patients who are selected for ASCT have already had considerable exposure to chemotherapy and radiation therapy. According to this reasoning, ASCT does not directly increase the risk for t-AML/MDS; it merely serves as a surrogate marker for patients who are at high risk due to extensive pre-transplant therapies.
In support of this hypothesis, most lymphoma patients have indeed been heavily treated before ASCT. Compared with the general population, multiple studies have demonstrated a significantly increased risk of t-AML/MDS in patients with either HL 32, 33, [36] [37] [38] [39] [40] [41] [42] [43] [44] or NHL. [45] [46] [47] These studies have consistently shown that the risk of t-AML/MDS is associated with increased exposure to alkylating agents, extent of radiation therapy and combined modality therapy. In addition, two retrospective case-control studies of Hodgkin lymphoma patients failed to show an increased rate of t-AML/MDS in autografted versus ungrafted patients. 11, 24 Therefore, considerable genotoxic damage may already exist, due to pre-ASCT therapy, in the hematopoietic cells in the product used for ASCT.
The hematopoietic precursors that lead to t-AML/MDS must reside either in the autologous stem cell product, or within residual host hematopoietic or non-hematopoietic (e.g., stromal) tissue, which survives the conditioning regimen. In the former case, pre-transplant therapy would be responsible for genotoxic damage, as the autologous stem cell product is not exposed to the conditioning regimen. In support of this concept, patients have been identified in whom the specific cytogenetic abnormalities that emerged with t-AML/MDS were found to be already present in the ASCT product, when sensitive techniques were applied retrospectively. 53, 54 The most common cytogenetic abnormalities seen after ASCT are those associated with exposure to alkylating agents (e.g., del(5q) or del(7q)) and topoisomerase II inhibitors (e.g., translocations involving 11q23). Again, these chemotherapy agents are frequently used in the initial and salvage therapies for lymphoma patients. Together, these observations provide evidence that pre-ASCT lymphoma therapy can cause significant genotoxic damage, leading to clonal abnormalities characteristic of t-AML/MDS.
Others have tracked clonality of hematopoiesis in lymphoma patients by assessing X chromosome inactivation patterns. Dysregulated (clonal) hematopoiesis was identified in 3% of NHL patients before ASCT, and was associated with a high risk of developing t-AML/MDS after ASCT. 55 This again suggests that pre-ASCT lymphoma therapy leads to genotoxic damage, which then causes the emergence of abnormal hematopoietic clones associated with t-AML/MDS. MDS and AML have been reported after transplantation for other malignancies, such as breast cancer, 49 ,50 multiple myeloma 51 and germ cell tumors. 52 The University of Arkansas group reported seven cases of MDS among 188 patients who underwent ASCT for myeloma. Interestingly, all of the patients who developed MDS had received prolonged treatment before ASCT. No cases of MDS were found among patients who received only one course of standard chemotherapy before ASCT, leading these investigators to conclude that pre-transplant therapy is likely to be the primary risk factor for t-MDS following ASCT for myeloma. 51 With regard to germ cell tumors, there is a small risk of t-AML/MDS, which appears to be very closely related to the cumulative dose of etoposide, and not increased by the ASCT procedure itself. 52 These observations argue that ASCT is unlikely to be the sole factor determining risk for t-AML/MDS.
Evidence that ASCT directly increases risk of t-AML/MDS
Despite the above evidence that pre-transplant therapies increase the risk of t-AML/MDS, ASCT could also Table 2 Factors associated with increased risk of AML/MDS after ASCT for lymphoma (seen in X2 studies)
Factor References Comments
Increased age 1, 4, 6, 11, 12, 14, 16, 24 'Increased age' variably defined as 35-44 years. TBI 1, 4, 12, [15] [16] [17] 20 Quantity of pre-transplant chemotherapy 2, 12, 13, 15, 18, 25 Pre-transplant radiation therapy 4, 8, 9, 16, 25 Lower stem cell content/difficult stem cell collection 3, 14, 18, 25 'Difficult' defined as requiring 45 days of apheresis. Pre-transplant alkylating agent exposure 2, 13, 20, 22 PBSC product 5, 6, 11, 20 Not found to be a risk factor by Sevilla et al. 18 Trend (P ¼ 0.12) reported by Metayer et al.
20
Time from diagnosis to transplant/number of relapses 9, 12, 14 Delayed platelet or ANC recovery post-transplant 2, 14, 19 Etoposide exposure 8, 17 Exposure during priming chemotherapy or conditioning regimen. Pre-transplant fludarabine exposure 14, 17 Refractory lymphoma 11, 15 Abbreviations: AML/MDS ¼ acute myeloid leukemia and myelodysplasia; ASCT ¼ autologous stem cell transplantation; PBSC ¼ peripheral blood stem cell; TBI ¼ total body irradiation.
theoretically contribute to the risk of t-AML/MDS in several ways. First, priming chemotherapy may induce genotoxic damage in HSCs, which are later infused during ASCT. Priming chemotherapy and/or the use of peripheral blood stem cell have been implicated as potentiating the risk of t-AML/MDS (see Table 2 ).
A second mechanism by which ASCT could increase the risk of t-AML/MDS relates to the conditioning regimen. High-dose chemotherapy or TBI, while not directly affecting an autologous stem cell product, could cause non-lethal genotoxic damage in residual marrow hematopoietic (and/or stromal) cells. The use of TBI in the ASCT conditioning regimen has been associated with an increased risk of t-AML/MDS by several groups, particularly in combination with etoposide (see Table 2 ). For many lymphoma patients undergoing ASCT today, the conditioning regimen (e.g. BEAM) is not truly myeloablative, increasing the chance that host hematopoietic cells will survive conditioning. In this setting, the conditioning regimen may be able to directly induce genotoxic damage and contribute to the risk of t-AML/MDS.
A third mechanism in which ASCT could contribute to t-AML/MDS pertains to the engraftment process. Following ASCT, there is a period of intense proliferation, as a relatively small proportion of the patient's HSC pool is called upon to reconstitute and maintain hematopoiesis long term. Assuming genotoxic damage already exists due to pre-transplant therapies, re-infusion of these damaged stem cells would impose a 'proliferative stress' on these cells during engraftment, which in turn would lead to expansion of pre-leukemic clones. The many replication cycles required for reconstitution after ASCT has been proposed to contribute to genomic instability through shortening of telomeres in descendent cells. 56 Decrease in telomere length is therefore one measurement of the proliferative stress that occurs during engraftment. A shortening of telomeres, followed by recovery to pre-transplant telomere lengths, has been described in patients recovering from ASCT. 57 Patients who are destined to develop t-AML/MDS show a reduced recovery of telomere length after ASCT, suggesting an excessive proliferative stress occurred during engraftment in those patients. 19, 57 Interestingly, a lesser degree of telomere shortening has been reported in patients recovering from allogeneic stem cell transplantation, possibly because allogeneic stem cell donors tend to be younger and have not been exposed to chemotherapy or radiation in the past. 58 In addition to abnormal telomere recovery, abnormal hematopoietic engraftment has been associated with an increased risk of t-AML/MDS after ASCT. Several studies have identified delayed platelet and/or neutrophil engraftment following ASCT for lymphoma as a risk factor for t-AML/MDS (see Table 2 ). Because recovery of peripheral blood cell counts and marrow cellularity may be an insensitive measure of hematopoietic reconstitution, Bhatia et al. 57 utilized colony-forming assays to quantitate the recovery of primitive and committed hematopoietic progenitor cells following ASCT. Patients who developed t-AML/MDS had a reduced recovery of committed progenitors at 1 year after ASCT. 57 These results indicate that delayed or insufficient engraftment is associated with an increased risk of t-AML/MDS. Abnormal engraftment is likely to be a reflection of a decreased quality and/or quantity of HSCs in the ASCT product. In such cases, there would be a particularly high proliferative stress during engraftment, which in turn would amplify abnormal clones bearing genotoxic damage from pre-transplant therapies. In support of this, several studies have identified a decreased dose of infused HSCs as a risk factor for t-AML/ MDS. 3, 14, 18 In addition, a recent report found an increased risk of t-AML/MDS in patients who required more than 5 days of apheresis, suggesting that a difficult stem cell harvest is a marker of marrow which has sustained significant genotoxic damage. 25 These observations support the notion that genotoxic damage initiated by pretransplant therapies may be amplified by the engraftment process, leading to the emergence of clonal abnormalities important in t-AML/MDS pathogenesis.
Evidence from randomized clinical trials
The most direct evidence to determine whether ASCT increases the risk of t-AML/MDS would be data from randomized controlled clinical trials. Ideally, such studies would be designed with a uniform pre-transplant therapy, followed by a randomization to ASCT versus observation, with extended (8-10 year) follow-up. Although no studies to date have all of these features, some important randomized studies of ASCT in lymphoma patients have been conducted.
In three of the four randomized studies of up-front ASCT in low-grade NHL, relatively low rates (0-3.8% at 5-7.5 years) of t-AML/MDS have been observed. 21, 22, 26 The low rate of t-AML/MDS in these studies supports the idea that ASCT early in the course of therapy (before patients have had extensive pre-transplant therapy) carries a lower risk of t-AML/MDS. However, this risk may still be significant, since in the fourth study (from the GOELAMS group), a rate of t-AML/MDS of 7.0% at 5 years was seen, with no cases observed in the chemotherapy alone group. 23 The increase in mortality due to second malignancies offset any survival benefit due to up-front ASCT. Of note, there were significant differences in the two arms of that study, making a direct comparison of the effect of ASCT alone difficult.
In aggressive NHL, there have been numerous randomized trials comparing a conventional chemotherapy regimen to a regimen that includes up-front ASCT. Seven studies have included 100 or more patients. [59] [60] [61] [62] [63] [64] [65] Very few cases of t-AML/MDS were reported in these studies. In addition, there were no cases of t-AML/MDS mentioned in the Parma study, which randomized relapsed aggressive NHL patients to conventional therapy versus ASCT. 66 However, due to the high-risk patient population in these studies, only 45-70% of patients survived 5 years or longer, and the median observation time for all of these studies was short (between 36 and 60 months). Because of these limitations, such reports are less informative on the issue of whether ASCT increases the risk of t-AML/MDS in aggressive NHL. As a result, these studies are not included in Table 1 .
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Pharmacogenetic risk factors for secondary AML/MDS
Recurrent acquired mutations in a variety of genes have been identified in both de novo and therapy-associated AML, suggesting a causative role for these genes in the pathogenesis of AML. 67, 68 Many of these mutations have been modeled in mice, providing further evidence of a key role for specific genes in leukemogenesis. In some cases, rare familial syndromes of de novo AML have also been identified, in which affected individuals have inherited polymorphisms of 'leukemogenesis' or 'leukemia pathway' genes such as RUNX1, C/EBPa, NF1 or TP53. [69] [70] [71] [72] For those with inherited polymorphisms of NF1 and TP53, there is also evidence of an increased risk for t-AML. 72, 73 Although such inherited genetic determinants can indeed increase the risks of both de novo and therapy-related AML, these particular polymorphisms are very rare and account for relatively few cases of de novo AML or t-AML in the general population. In contrast, other more common polymorphisms have now been identified in 'leukemia pathway' genes. [74] [75] [76] With regard to t-AML in particular, NRAS, KRAS, RUNX1 and TP53 are particularly good candidate t-AML susceptibility genes, since (a) mutations in these genes have been seen in 20-30% of t-AML cases, (b) mutations are more frequently seen in t-AML than in de novo AML and (c) inherited single nucleotide polymorphisms have been identified in these genes.
In addition to such 'leukemia pathway' genes, a number of recent studies have found associations between t-AML/ MDS and polymorphisms in genes involved in drug metabolism and DNA repair (see Table 3 ). 74 Three classes of genes involved in metabolism of chemotherapy drugs have been implicated in t-AML/MDS. The cytochrome P450 enzymes play an important role in the phase I metabolism of topoisomerase II inhibitors, and also have been shown to act on cyclophosphamide. In two studies, a Repair of single strand breaks Abbreviations: t-AML/MDS ¼ therapy-related acute myeloid leukemia and myelodysplasia; NAD(P)H ¼ nicotinamide adenine dinucleotide phosphate.
Secondary AML/MDS post-ASCT CR Hake et al polymorphism in the 5 0 promoter of CYP3A4 was associated with t-AML. 81, 82 For other cytochrome P450 enzymes such as CYP2C19 and CYP2D6, there are conflicting data regarding association of poor metabolizer alleles with t-AML. 83, 90 Several genes encoding glutathione transferases contain polymorphisms, which are potentially of functional significance. In particular, the Val105 allele of GSTP1 has been associated with an increased risk of t-AML. 84 NAD(P)H:quinine oxidoreductase (NQO1) is important for reduction of potentially carcinogenic quinone metabolites. A loss-of-function polymorphism at codon 187 has been associated with an increased risk of t-AML by two independent groups. 85, 86 Other associations have been identified between various drug metabolism gene polymorphisms and de novo AML. In general, these associations have been relatively weak, and their relevance for t-AML is not yet known. 74, 91 Inherited polymorphisms in molecules important for the different DNA repair mechanisms may influence an individual's susceptibility to a variety of malignancies. Germline variations in XPD, MSH2 and XRCC1 have been identified, which confer an increased risk of t-AML (see Table 3 ). These genes play important roles in excision repair, mismatch repair and single-strand break repair, respectively.
In addition to the above human case-control data, we recently developed a mouse model that provides evidence that genetic determinants influence susceptibility to alkylator-induced malignancies. In this study, we exposed 20 genetically diverse, inbred strains of mice to the prototypical alkylating agent N-nitroso-N-ethylurea (ENU). We found that certain strains of mice developed a high (30-80%) rate of myeloid malignancies, following exposure to ENU. In contrast, in several other strains, no cases of myeloid malignancies were observed. 92 These results provide additional evidence that susceptibility to alkylatorinduced AML/MDS is indeed influenced by inherited genetic polymorphism.
Multi-step mechanism for development of t-AML/MDS
As discussed above, multiple independent groups have identified pre-transplant factors associated with increased risk of t-AML/MDS, such as age, overall extent of pretransplant chemotherapy or radiation, and exposure to specific agents such as alkylating agents or etoposide (see Table 2 ). In addition, factors relating to the stem cell product have also been implicated as risk factors for t-AML/MDS, such as the type of priming chemotherapy used, source of stem cells, number of CD34-positive or mononuclear cells infused, number of apheresis procedures required, and the presence of cells with cytogenetic abnormalities in the stem cell product. These findings all suggest that the risk of t-AML/MDS is in part determined before ASCT. However, components of the conditioning regimen (in particular, TBI) have also been shown to increase the risk of t-AML/MDS. In addition, it appears increasingly clear that variables in the engraftment process may contribute to the risk of t-AML/MDS. Specifically, the 'proliferative stress' imposed by engraftment may lead to the positive selection of stem cells with genotoxic damage initiated by pre-transplant therapy. In addition, there is now evidence suggesting that certain inherited polymorphisms in genes governing drug metabolism, DNA repair and leukemogenesis can predispose individuals to t-AML/MDS (see Table 3 ). be at risk for t-AML/MDS due to high-risk genetic polymorphisms. Genotoxic stress due to pre-transplant chemoradiotherapy, priming chemotherapy and TBI leads to a significant increase in risk for t-AML/MDS. The proliferative stress associated with engraftment further increases the risk for t-AML/MDS by amplifying the genotoxic damage initiated by pre-transplant therapies.
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We therefore hypothesize that the mechanism of t-AML/ MDS following ASCT is multifactorial, involving primarily (1) genotoxic damage to HSCs caused by advancing age and chemoradiotherapy administered before ASCT, (2) proliferative stress imposed on hematopoietic cells during engraftment and (3) inherited polymorphisms in genes that govern drug metabolism, DNA repair and leukemogenesis. As shown in Figure 1 , the model assigns the majority of the risk of t-AML/MDS to pre-transplant factors (prior therapy, age, high risk polymorphisms), but also assigns some risk to events occurring from the time of stem cell priming onward.
Strategies to decrease t-AML/MDS
With several different factors controlling the risk of t-AML/MDS, numerous strategies could be proposed to decrease the risk of t-AML/MDS in lymphoma patients undergoing ASCT. We have listed several such potential interventions in Table 4 . It should be emphasized that these strategies have not been proven to reduce the risk of t-AML/MDS, and in individual cases may not be feasible given other clinical or logistical constraints. Strategies that could immediately be implemented would include minimizing use of alkylating agents or etoposide in the primary or secondary therapy of lymphoma patients, increasing the dose of CD34-positive cells infused during ASCT, or banking autologous stem cells earlier in the course of patient management. In addition, further development of emerging tools (such as interim positron emission tomography/computed tomography scans, 93 revised prognostic scoring systems, 94 and DNA/tissue microarrays 95 ) to more accurately identify high-risk NHL patients who might benefit from ASCT in first remission, will allow for a more judicious application of ASCT. Perhaps the approach with the widest potential applicability would be the development of genetic screening tests to identify patients at high risk for t-MDS/t-AML. Such assays would have the potential to influence clinical decision making early in the management of lymphoma patients. This could include offering alternatives to high-dose alkylating agent or TBI-containing conditioning regimens in patients felt to be at particularly high risk for t-AML/MDS. Reduce pre-transplant exposure to alkylating agents and etoposide.
Bank stem cells earlier in disease process. Decreased genotoxic damage in stem cell product.
Perform ASCT, if needed, earlier in disease course. Decreased genotoxic stress going into ASCT.
Be more selective in choosing patients to undergo ASCT in CR1. Some patients in CR1 are already cured of their lymphoma, and ASCT may increase risk of t-MDS/AML without improving survival. This may be particularly true in the rituximab era. New tools (such as interim PET/CT, 93 revised prognostic scoring systems, 94 and DNA/tissue microarrays 95 ) may prove to be more accurate than IPI score for prognostication.
Screen patients for surrogate markers of early/impending MDS before stem cell collection.
Patients with cytogenetic abnormalities of MDS are at higher risk for progressing to t-AML after ASCT.
Stem cell collection/transplant interventions
Avoid etoposide in priming chemotherapy. Etoposide in priming therapy associated with increased risk of t-AML/ MDS. Non-etoposide salvage/priming regimens (e.g., gemcitabinecontaining regimens) may have similar activity in relapsed/refractory lymphoma patients. [96] [97] [98] Infuse higher doses of autologous stem cells. Decrease proliferative stress during engraftment.
Consider approaches other than ASCT in patients for whom stem cell collection proves difficult.
Patients who require 45 apheresis sessions, or who have lower CD34 cells collected have higher risk of t-AML/MDS.
Use TBI conditioning in only select cases. TBI shown in several studies to increase risk of t-AML/MDS.
Post-transplant interventions
Monitor closely for impending t-AML/MDS post-transplant. Disease-modulating MDS therapies may eventually be proven to alter natural history of t-AML/MDS.
Abbreviations: ASCT ¼ autologous stem cell transplantation; HL ¼ Hodgkin's lymphoma; NHL ¼ non-Hodgkin's lymphoma; PET/CT ¼ positron emission tomography/computed tomography; t-AML/MDS ¼ therapy-related acute myeloid leukemia and myelodysplasia; TBI ¼ total body irradiation.
Conclusions
Lymphoma patients who have undergone ASCT have a significant risk for developing t-AML/MDS. The most consistent and powerful risk factors identified to date are age, TBI and the quantity of pre-transplant therapy. The extent that non-TBI conditioning regimens contribute to t-AML/MDS risk is still uncertain; however, there is an increasing body of evidence to suggest that salvage therapy, stem cell priming and/or suboptimal engraftment add to the risk of t-AML/MDS in certain patients. Strategies to more carefully select patients for ASCT, to minimize exposure to leukemogenic agents before stem cell collection, and to analyze inherited genetic polymorphisms predisposing to t-AML/MDS may allow identification of individual patients at particularly high risk for t-AML/ MDS. Consideration of alternatives to ASCT may be warranted in such patients.
